VLS Tirzepatide Pen

📅 August 17, 2026 ⏱️ 2 min read ✍️ Team TPS

The VLS Tirzepatide Pen is the dual agonist in pre-filled form, the best-evidenced of the newer GLP-1 compounds.

What tirzepatide does

Tirzepatide agonises two receptors: GLP-1 and GIP. Semaglutide covers GLP-1 alone, and the GIP addition is what separates the two generations.

Both act on appetite, insulin response and gastric emptying. The practical result is substantially reduced intake without the effort that normally requires. See semaglutide vs tirzepatide vs retatrutide.

Why it is the safer starting point

Of the compounds in this class, tirzepatide has the most extensive and longest-running research behind it. Retatrutide is newer, more aggressive and less characterised.

If this is a first GLP-1, that evidence gap is a reasonable thing to weigh. See tirzepatide vs retatrutide.

The pen

The VLS Tirzepatide Pen arrives pre-filled and in solution. No powder, no bacteriostatic water, no volume decision, and the clock does not start until first use.

That removes the steps where errors normally happen. See reconstitution and bacteriostatic water for what a vial asks of you instead.

Reading the dial

Units are volume, not milligrams. A 20mg pen and a 40mg pen deliver different amounts at the same dial number, and so does a SerenQ pen at that number.

Calculate the per-unit figure for the pen in your hand and write it down, how to read a peptide pen dial.

What to expect early

Nausea, early fullness and altered digestion, most pronounced at the start and after each increase. They come from slowed gastric emptying, which is the mechanism rather than a fault. See GLP-1 side effects explained.

Protein falls first when appetite drops, and that is what costs people muscle rather than the compound itself, GLP-1s and muscle retention.

Handling

Refrigerate between uses, fresh tip every time, prime until you see a droplet, and never let it freeze. See your first week with a peptide pen and the VLS range.

Supplied for research purposes only.